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Abstract
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, 
proliferation, angiogenesis, and survival, and additionally plays an important role in immune regulation. Since mTOR inhibi-
tors were shown to benefit immunosuppressive regulatory T-cell (Treg) expansion, this might suppress antitumor immune 
responses. Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs. This study was, therefore, designed 
to determine the optimal dosage and schedule of CTX when combined with everolimus to prevent this potentially detrimental 
Treg expansion. In this national multi-center phase I study, patients with mRCC progressive on first line anti-angiogenic 
therapy received 10 mg everolimus once daily and were enrolled into cohorts with different CTX dosages and schedules. 
Besides immune monitoring, adverse events and survival data were monitored. 40 patients, 39 evaluable, were treated with 
different doses and schedules of CTX. Combined with 10 mg everolimus once daily, the optimal Treg depleting dose and 
schedule of CTX was 50 mg CTX once daily. 23 (59%) patients experienced one or more treatment-related ≥ grade 3 tox-
icity, mostly fatigue, laboratory abnormalities and pneumonitis. The majority of the patients achieved stable disease, two 
patients a partial response. Median PFS of all cohorts was 3.5 months. In conclusion, the optimal Treg depleting dose and 
schedule of CTX, when combined with everolimus, is 50 mg once daily. This combination leads to acceptable adverse events 
in comparison with everolimus alone. Currently, the here selected combination is being evaluated in a phase II clinical trial.
Trial registration NCT01462214.
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PD  Progressive disease
PFS  Progression-free survival
PR  Partial response
RCC  Renal cell carcinoma
SD  Stable disease
Treg  Regulatory T cell
VEGF  Vascular endothelial growth factor
WIN-O  Dutch Working Group on Immuno-
therapy of Oncology
Introduction
In 2017, 63,990 new cases and 14,400 deaths due to kid-
ney cancer are estimated in the United States and thereby 
it belongs to the 10 most common cancers in both men and 
women [1]. The most common tumor arising in the kidney 
is renal cell carcinoma (RCC). Due to new techniques the 
histological classification has changed. Though clear cell, 
papillary and chromophobe RCC are still the most com-
mon subtypes, a total of more than 10 subtypes can now 
be identified [2]. The treatment of metastatic RCC (mRCC) 
has radically changed over the past 10 years. After years 
with limited treatment options, when interferon-α and 
interleukin-2 achieved response rates in only 10–20% of 
the patients, inhibitors of the vascular endothelial growth 
factor (VEGF)—signaling pathway and inhibitors of the 
mammalian target of rapamycin (mTOR), such as temsiroli-
mus and everolimus, were introduced as first and second 
line treatment options respectively [3]. More recently an 
inhibitor of the PD-1 immune checkpoint, nivolumab [4], 
and cabozantinib, a multi-tyrosine kinase inhibitor of MET, 
AXL and VEGF [5, 6] were shown to be more effective 
in clinical trials compared to everolimus, thereby replacing 
everolimus as the standard second line therapy after VEGF 
targeted therapy [7]. In addition, the combination of everoli-
mus and the multi-target tyrosine kinase inhibitor lenvatinib 
improved progression-free survival (PFS) in patients with 
mRCC compared to everolimus alone following one prior 
anti-angiogenic therapy [8, 9].
Everolimus was shown to be an effective inhibitor of 
mTOR, resulting in the inhibition of cell growth, prolifera-
tion, angiogenesis and survival of tumor cells. In addition, 
mTOR plays an important role in immune regulation, by 
balancing effector T cells and regulatory T cells (Tregs) 
[10–13]. Tregs are important regulators of immunological 
tolerance and dependent on the transcription factor FoxP3 
for their immune suppressive functionality [14, 15]. mTOR 
inhibition was shown to result in Treg expansion [16–18] and 
increased levels of Tregs have been associated with poor sur-
vival in cancer patients, including mRCC [19–21]. Recently, 
we and others reported that everolimus leads to Treg pro-
liferation, both in vitro and in vivo [22–24]. Metronomic 
administration of CTX has been reported to result in Treg 
depletion, with possible beneficial effects on T- and NK-
cell functionality [25, 26]. Therefore, we hypothesized that 
addition of metronomic CTX to therapy with everolimus in 
patients with mRCC might counteract the detrimental Treg 
expansion induced by everolimus and could thereby increase 
the antitumor efficacy. In this phase I study we aimed to 
determine the optimal dose of CTX that would result in the 
selective depletion of Tregs when combined with a fixed 
dose (10 mg) of everolimus, taking into account the safety 
and tolerability of the combination treatment.
Patients and methods
Patients
Between January 2012 and August 2015, patients were 
enrolled in this clinical trial initiated by the department of 
medical oncology of the VU University Medical Center and 
conducted within the context of the Netherlands Working 
Group on Immunotherapy of Oncology (WIN-O) with par-
ticipation of 13 hospitals. Main inclusion criteria for this 
trial were an age of 18 years or older, clear-cell mRCC and 
progression on treatment with a VEGF receptor tyrosine 
kinase inhibitor. In addition, patients had to have adequate 
hematologic, hepatic and renal function, measurable or 
evaluable disease as defined by RECIST 1.1 and a WHO 
performance status of 0–2. A more detailed description of 
in- and exclusion criteria can be reviewed in the previously 
published study protocol [27]. Follow-up was performed 
until death or at trial analysis, 2 years after inclusion of the 
last patient.
Treatment
Patients were treated with different doses and schedules 
of low-dose oral CTX in combination with a fixed dose of 
everolimus once daily. CTX was either given in a week-on/
week-off schedule or continuously and either once or twice 
daily. These doses and schedules were based on the CTX 
doses used by Ghiringhelli et al. [26]. Patients were enrolled 
in cohorts of five patients per dose level. In dose level 6, 
one patient stopped treatment because of several toxicities 
(highest grade 3 nausea) within 2 weeks of enrollment and 
was not evaluable. In case of severe toxicity dose reductions 
were allowed.
The first five patients were enrolled in an everolimus 
only cohort with 10 mg everolimus. Subsequently five 
patients were treated in cohort 1 with the combination 
of 10 mg everolimus and 50 mg CTX once daily, week-
on/week-off. In cohort 2 patients were treated with the 
combination of everolimus and 50 mg CTX once daily, 
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continuously. In cohort 3 patients received 50 mg CTX 
twice daily, week-on/week-off, and in cohort 4 patients 
received 50 mg CTX twice daily, continuously. In the last 
two cohorts, cohort 5 and 6, respectively, patients received 
100 mg CTX twice daily, in cohort 5 in a week-on/week-
off regimen and in cohort 6 continuously.
Study objectives
The primary objectives of the study were to determine a 
recommended dose and schedule for metronomic cyclo-
phosphamide which, when combined with the standard 
once daily oral dose of 10 mg of everolimus, resulted 
in optimal and selective Treg depletion in patients with 
mRCC and to determine the safety and tolerability of this 
combination. Secondary study objectives included (a) 
assessment of effects on various immune cell populations, 
(b) effects on selected angiogenesis parameters, (c) the 
effect of cyclophosphamide on everolimus drug levels, and 
(d) clinical outcome measures such as response rate, time 
to progression, and OS.
Evaluation of toxicity and clinical activity
Patients were treated in cohorts of 5 patients per dose 
level. In case of no more than 1 dose limiting toxicity 
(DLT) in a cohort within the 28 days after start of the 
study treatment, it was allowed to proceed to the next dose 
level. DLTs were defined as febrile neutropenia, neutro-
penic infection, other grade ≥ 3 hematological toxicity, 
pneumonitis, nausea, vomiting, diarrhea, fatigue or any 
other grade ≥ 3 adverse event that, despite appropriate 
supportive care, failed to recover to grade ≤ 1 or baseline 
severity (or grade ≤ 2 at the investigator’s and sponsor’s 
discretion) after delaying the next cycle for up to 7 days.
Response to treatment was assessed by the use of 
RECIST version 1.1. Evaluable patients were defined as 
those patients completing at least 2 weeks of combination 
therapy, i.e., allowing the monitoring of immunological 
effects at time point 2 weeks. Furthermore, patients were 
evaluated for their performance status, vital signs, general 
laboratory parameters and immune monitoring at baseline 
and after 2, 4 and 8 weeks of treatment and every 4 weeks 
for their clinical condition and general laboratory param-
eters until the end of study treatment. CT scans of the 
chest and abdomen were made at baseline and thereafter 
every 8 weeks. Patients receiving any study treatment were 
evaluable for safety. Adverse events were graded according 
to the National Cancer Institute Common Toxicity Criteria 
(CTC) grading system version 3.0 (NCI-CTCAE v3.0).
Immune monitoring
Peripheral blood was collected for extensive monitoring at 
baseline and subsequently at 2, 4, and 8 weeks after the 
start of the study treatment period and at the end of study 
treatment. For immune monitoring 60 mL of heparinized 
peripheral blood was collected. All material was processed 
on the same day the blood was drawn. In this manuscript, we 
present immune monitoring data of the effects of the various 
treatment cohorts on the induction of Treg depletion, the 
primary objective of this study. The effects of the various 
treatment cohorts on other immunological parameters will 
be comprehensively published separately.
PBMC were isolated from heparinized blood of patients 
by density-gradient centrifugation with Lymphoprep (Axis-
Shield, Oslo, Norway). After isolation PBMC were stored 
overnight at 4 °C in RPMI 1640 (Lonza, Basel, Switzerland) 
supplemented with 100 IU/ml sodium penicillin (Astellas 
Pharma, Leiden, the Netherlands), 100 mg/ml streptomycin 
sulfate (Radiumfarma-Fisiofarma, Naples, Italy), 2.0 nM 
l-glutamine (Life Technologies, Bleiswijk, the Nether-
lands), 10% FBS (HyClone, Amsterdam, the Netherlands), 
and 0.05 mM 2-ME (Merck, Darmstadt, Germany), hereafter 
referred to as complete medium. The next day cells were 
stained for flow cytometric analysis.
PBMC were analyzed by flow cytometry using FITC-, 
PerCP- or allophycocyanin (APC)-labeled Abs directed 
against human CD3, CD4, and CD25 (all BD Biosciences, 
New Jersey, USA). Stainings were performed in PBS sup-
plemented with 0.1% BSA and 0.02% sodium azide for 
30 min. Intracellular staining was performed after fixation 
and permeabilization using a fixation/permeabilization kit 
according to the manufacturer’s protocol (eBioscience). For 
staining of FoxP3 a PE-labeled Ab against FoxP3 (clone 
PCH101, eBioscience) was used. Live cells were gated 
based on forward and side scatter and analyzed on a BD 
FACSCalibur (BD Biosciences) using Kaluza Analysis Soft-
ware (Beckman Coulter).
VEGF measurements
Plasma VEGF concentrations were measured in heparin 
plasma, frozen the day the material was received and stored 
at − 20 °C until analysis, using a commercially available 
ELISA kit (Quantikine, R&D Systems, Abingdon, UK) 
according to the manufacturers’ instructions. Absorbance 
was measured using a BioTek Synergy HT plate reader with 
an optical density of 450 nm.
Statistical analysis
One-way repeated measures ANOVA was used to determine 
the statistical significance of differences within cohorts with 
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Dunnett’s Multiple Comparison test as post-test. Two-way 
ANOVA was used to compare the mean values between 
cohorts. PFS was defined as time from baseline till pro-
gression or death, OS was defined as time from baseline till 
death. Both PFS and OS were analyzed using Kaplan–Meier 
curves. Differences were considered statistically significant 
when p values were ≤ 0.05, as indicated with asterisks 
(*p ≤ 0.05, **p < 0.01, ***p < 0.001). Statistical analyses 
were performed using GraphPad Prism software (version 
7, 2016).
Results
Patient characteristics
Between January 2012 and August 2015, a total of 54 
patients were screened for this study in 10 different hospi-
tals in the Netherlands. Of these 54 patients, 10 patients did 
not meet the inclusion criteria while 3 patients withdrew 
their consent either before start or within the first 2 weeks of 
study treatment. In addition, 1 patient was excluded because 
of inadvertent administration of the wrong dose of study 
medication, while another patient was not evaluable due to 
early toxicity and subsequent interruption of study medi-
cation and withdrawal of informed consent; therefore, 39 
patients were analyzed in the study. Patient characteristics 
are shown in Table 1 and supplementary table 1.
From the 39 patients, 64% were male. The median age 
of participating patients was 66 years, 20.5% received more 
than one prior line of systemic therapy, and 72% of patients 
were in the favorable or intermediate IMDC (International 
Metastatic Renal-Cell Carcinoma Database Consortium) 
risk group (Table 1).
Patients were discontinued from study therapy because 
of progression (n = 25, 64%), unacceptable toxicity (n = 12, 
30%) or death (n = 2, 5%). Follow-up was performed until 
death (n = 36) or until time of analysis of the trial (n = 3).
Treg depletion
The main objective of this phase 1 trial was to determine the 
optimal dose and administration schedule of orally admin-
istered CTX, when combined with 10 mg everolimus, to 
obtain selective Treg depletion. As shown in Fig. 1a, a (non-
significant) increase in Treg percentages within the  CD4+ 
T-cell population was observed in the everolimus only 
cohort, cohort 0. In cohort 1, 50 mg CTX was administered 
in a week-on/week-off schedule. Compared to the everolimus 
only cohort, a significant decrease in Treg percentages at 
time point 4 was observed. In the next cohort, cohort 2, in 
which 50 mg CTX was administered in a continuous sched-
ule, a significant decrease in Treg percentages within the 
cohort was observed when comparing the percentages at 
time point 0 to time point 4. In addition, a significant dif-
ference in Treg percentages between cohort 0 and cohort 2 
was observed at time point 4, using the two-way ANOVA. 
Supplementary Fig. 1. shows representative flow cytom-
etry dot plots illustrating the changes in Treg percentages. 
Table 1  Clinical characteristics
a International mRCC Database Consortium or Heng criteria
b Adrenal gland, soft tissue, pleural space, muscle, peritoneum/mesen-
teries, pancreas, vagina, spleen, pericardial tissue
Characteristic Study group (n = 39)
Median age—year (range) 66 (44–78)
Sex—no. (%)
 Male 25 (64)
 Female 14 (36)
ECOG performance status—no. (%)
 0 14 (36)
 1 20 (51)
 2 4 (10)
 Unknown 1 (2.6)
IMDC risk  groupa
 Favorable 4 (10)
 Intermediate 24 (62)
 Poor 9 (23)
 Unknown 2 (5)
Median time from initial diagnosis to meta-
static disease—months (range)
9 (0–134.5)
Median time from metastatic disease to start of 
study treatment—months (range)
17 (0.8–290)
Site of metastasis—no. (%)
 Lung 30 (77)
 Lymph nodes 24 (62)
 Bone 8 (21)
 Kidney 7 (18)
 Liver 5 (13)
 Brain 1 (2,6)
 Otherb 21 (54)
Number of metastatic sites
 1 7 (18)
 2 13 (33)
 3 9 (23)
 ≥ 4 10 (26)
Previous systemic cancer therapy
 Sunitinib 33 (85)
 Pazopanib 9 (23)
 Sorafenib 3 (7.6)
 Interferon +/_ bevacizumab 3 (7.6)
 IL-2 1 (2.6)
Previous anti-angiogenic regimens—no. (%)
 1 31 (80)
 ≥ 1 8 (20)
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Proceeding to the following cohorts, the Treg depleting 
effect of CTX was progressively less pronounced. Of inter-
est, in the last 2 cohorts, cohort 5 with administration of 
100 mg CTX twice daily in a week-on/week-off schedule 
and cohort 6 with administration of 100 mg CTX twice daily 
in a continuous schedule, we even observed an increase in 
Treg percentages. Notably, changes in absolute Treg num-
bers generally followed the same patterns as observed for 
changes in Treg percentages. A significant decrease was 
observed in cohort 2 comparing Treg numbers at week 0 
with week 4, while absolute Tregs numbers did not change 
or even increased in subsequent cohorts (Fig. 2a). Therefore, 
the decision was made to end the dose escalation phase of 
the study, and to proceed to the expansion cohort, in which 
an additional 5 patients were treated with the optimal Treg 
depleting dose observed in cohort 2. In none of the tested 
cohorts significant changes in  CD4+ T cell percentages were 
observed. Comparing the  CD4+ T cell percentages in the 
individual cohorts with cohort 0, we did find a significant 
difference at week 4 between cohort 0 and the expansion 
cohort (see Supplementary Fig. 2). Lymphocyte percentages 
increased within cohort 3, 4 and 5 at week 2 and decreased 
in cohort 6 at week 4. This resulted in significant differences 
between cohort 0 and cohort 5 and 6 in the first 4 weeks and 
only at week 4 of the study, respectively (see Supplementary 
Fig. 3).
The expansion cohort essentially confirmed the results 
previously observed in cohort 2. Again, a decrease in Treg 
percentages was noted between time point 0 and 4 resulting 
in a statistically significant difference at this time point in 
Treg percentages between cohort 0 and the expansion cohort. 
When the results of cohort 2 and the expansion cohort were 
combined, a highly significant decrease in the percentage of 
Tregs was observed, both within the combined patient cohort 
Fig. 1  Effect of different dosages and administration schedules of 
CTX when combined with a fixed dose of 10 mg everolimus on the 
frequency of Tregs. a Relative percentages of Tregs within  CD4+ 
T cells were determined in freshly isolated PBMC from patients 
treated with different dosages and schedules of CTX, combined 
with a fixed dose of everolimus at baseline and subsequently 2, 4, 
and 8 weeks after start of treatment. p value indicated with asterisk; 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, xp = 0.07. b Relative percentages 
of Tregs within  CD4+ T cells are shown for cohort 2 combined with 
the expansion cohort. Patients were treated with 50  mg CTX once 
daily, combined with 10  mg everolimus once daily. Means ± SEM 
are shown; p value indicated with asterisk; *p ≤ 0.05, **p ≤ 0.01, 
****p ≤ 0.0001
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as well as in comparison of this cohort to cohort 0 (Fig. 1b). 
In absolute Treg numbers the same decrease was observed 
in the expansion cohort, with a significant difference at time-
point 4 between cohort 0 and the expansion cohort. When 
absolute number data from cohort 2 were combined with 
those of the expansion cohort 2E, a significant decrease in 
absolute Treg numbers was noted (Fig. 2b).
Adverse events and DLT
During the entire study 314 adverse events were reported; 
93 of these consisted of laboratory abnormalities (see 
Table 2 and supplementary table 2). The most common 
treatment-related toxicities (> 30%) included fatigue 
(n = 18; 46%), anorexia (n = 16; 41%), rash (n = 15; 38%), 
cough (n = 14; 36%), mucositis (n = 14; 36%), nausea 
(n = 12; 31%), anemia (n = 14; 36%), and hypercholester-
olemia (n = 12; 31%). The mean number of adverse events 
of any grade was 8.2 per patient in the total group, while a 
mean of 5.4 adverse events per patient occurred in cohort 
0 (i.e., in the cohort without CTX). When patients were 
treated for a longer period with the study drugs, more 
adverse events were reported. When adjusted, a mean 
of 3.2 adverse events per month was reported. After this 
adjustment, the two cohorts with the highest CTX dose 
showed slightly more adverse events compared to the 
lower cohorts.
47 treatment-related ≥ grade 3 toxicities were reported in 
22 patients, and these consisted mainly of laboratory abnor-
malities (leukocytopenia, lymphocytopenia, hyperglycemia) 
and fatigue. One patient suffered from grade 4 lymphopenia 
after 10.5 months of treatment in cohort 5 in which 10 mg 
everolimus was combined with 100 mg CTX twice daily in 
a week-on/week-off schedule. A dose reduction had already 
taken place because of the toxicity, which had been present 
at a lower grade for a longer period. The grade 4 toxicity 
Fig. 2  Effect of different dosages and administration schedules of 
CTX when combined with a fixed dose of 10 mg everolimus on abso-
lute Treg numbers. a Relative percentages of absolute Treg numbers 
were determined in freshly isolated PBMC from patients treated with 
different dosages and schedules of CTX, combined with a fixed dose 
of everolimus at baseline and subsequently 2, 4, and 8  weeks after 
start of treatment. p value indicated with asterisk, *p ≤ 0.05. b Rela-
tive percentages of absolute Treg numbers are shown for cohort 
2 combined with the expansion cohort. Patients were treated with 
50 mg CTX once daily, combined with 10 mg everolimus once daily. 
Means ± SEM are shown; p value indicated with asterisk; *p ≤ 0.05
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eventually lead to the decision to stop the study medication, 
followed by the radiological assessment of disease progres-
sion several days later.
Two patients experienced ≥ grade 3 toxicity within the 
first 28 days after start of the study treatment, one grade 3 
pneumonitis and one grade 3 pancytopenia in combination 
with hyperglycemia. The patient with the grade 3 pneumoni-
tis was treated in cohort 1, in which 10 mg of everolimus was 
combined with 50 mg CTX once daily in a week-on/week-off 
schedule. According to the protocol everolimus was inter-
rupted resulting in improvement of the pneumonitis. Study 
medication was permanently discontinued and dyspnea per-
sisted 46 days after the initiation of treatment and the patient 
showed radiological signs of progressive disease 10 days 
later. The patient with grade 3 pancytopenia in combination 
with hyperglycemia was treated in cohort 5, in which 10 mg 
everolimus was combined with 100 mg CTX twice daily in 
a week-on/week-off schedule. The adverse event occurred 
after 12 days of study drug administration and according to 
the protocol the treatment was temporarily stopped. Labo-
ratory values improved and after 9 days of interruption 
both study drugs were restarted at half the original dose. 
Although both ≥ grade 3 toxicities occurred within the first 
28 days from start of combination treatment, both occurred 
in different cohorts. Since ≤ 1 DLTs were experienced by the 
5 patients in these cohorts, further patients could be enrolled 
at the next dose level.
Both in cohort 2, the cohort that showed a selective Treg 
depletion, as well as in the similarly dose expansion cohort, 
three grade 3 adverse events were reported and no DLTs.
VEGF levels
As chemotherapy was proposed to have anti-angiogenic 
effects in metronomic doses (reviewed in [28]), several 
studies showed decreased VEGF levels after treatment with 
metronomic CTX [29, 30]. For this study VEGF levels were 
measured at baseline, week 4 and (where available) week 8. 
The mean baseline VEGF level of all patients included in 
the study was 210 ± 30 pg/ml (mean ± SEM). As shown in 
supplementary Fig. 4, all cohorts in which patients received 
the combination treatment of everolimus and CTX showed 
lower VEGF levels during treatment as compared to cohort 
0 in which patients received everolimus monotherapy. The 
cohorts with higher doses of CTX showed more pronounced 
effects; however, in neither of the cohorts, results were sta-
tistically significant.
Clinical outcome
The Overall Response Rate (ORR) did not significantly 
differ between the investigated cohorts. The best clinical 
response was a partial remission (PR) in 2 patients (5%); 
Table 2  Treatment-related toxicity
Reported in 10% or more of the treated patients
a Hypophosphatemia, hyponatremia, hypo- and hyperkalemia, hypo-
calcemia
b Alanine aminotransferase, aspartate aminotransferase, gamma-gluta-
myl transferase and alkaline phosphatase
Event Any Grade Number of patients (%)
Grade 1 Grade 2 Grade ≥ 3
Neurology
 Neuropathy 4 (10) 3 (8) 1 (3) 0
Respiratory
 Cough 14 (36) 11 (28) 3 (8) 0
 Dyspnea 10 (26) 5 (13) 4 (10) 1 (3)
 Pneumonitis 7 (18) 1 (3) 3 (8) 3 (8)
Gastro-intestinal
 Mucositis 14 (36) 10 (26) 4 (10) 0
 Nausea 12 (31) 6 (15) 6 (15) 0
 Diarrhea 11 (28) 8 (20) 1 (3) 2 (5)
 Vomiting 9 (23) 4 (10) 5 (13) 0
 Dysgeusia 6 (15) 4 (10) 2 (5) 0
 Stomatitis 5 (13) 3 (8) 1 (3) 1 (3)
 Constipation 4 (10) 1 (3) 3 (8) 0
Renal/genitourinary
 (Hemorrhagic) cystitis 7 (18) 2 (5) 4 (10) 1 (3)
 Pollakisuria 4 (10) 3 (8) 1 (3) 0
Constitutional
 Fatigue 18 (46) 5 (13) 8 (20) 5 (13)
 Anorexia 16 (41) 8 (20) 8 (20) 0
 Fever/chills/flu 5 (13) 5 (13) 0 0
 Malaise 4 (10) 2 (5) 1 (3) 1 (3)
Dermatology
 Rash 15 (38) 9 (23) 6 (15) 0
 Dry skin 8 (20) 6 (15) 2 (5) 0
 Pruritus 4 (10) 4 (10) 0 0
Laboratory
 Anemia 14 (36) 2 (5) 10 (26) 2 (5)
 Hypercholesterolemia 12 (31) 3 (8) 7 (18) 2 (5)
 Lymphocytopenia 10 (26) 0 2 (5) 8 (20)
 Hyperglycemia 10 (26) 1 (3) 6 (15) 3 (8)
 Thrombocytopenia 10 (26) 7 (18) 1 (3) 2 (5)
 Hypertriglyceridemia 8 (20) 3 (8) 3 (8) 2 (5)
 Leukocytopenia 8 (20) 2 (5) 2 (5) 4 (10)
 Electrolyte  disturbancea 7 (18) 5 (13) 0 2 (5)
 Liver values  increasedb 6 (15) 2 (5) 3 (8) 1 (3)
 Neutropenia 5 (13) 0 3 (8) 2 (5)
Other
 Edema (extremities/
face)
4 (10) 3 (8) 0 1 (3)
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stable disease (SD) was observed in 22 patients (56%) and 
progressive disease (PD) in 15 patients (39%) (Fig. 3a). The 
responses per cohort are shown in Fig. 3b.
Median PFS among all cohorts was 3.5 months (range 
1–24 months). At the end of the follow-up period 1 patient 
did not show progression, however, this patient stopped 
study treatment after 8  weeks due to toxicity. After 
8.5 months this patient still did not show progression, and 
was lost to follow-up after 25 months. No significant differ-
ences in PFS were observed between the different cohorts. 
In Fig. 4 the PFS is shown per cohort. There was no sta-
tistically significant correlation between Treg numbers and 
PFS (R = 0.01, p = 0.47; data not shown). Median OS was 
11.5 months (range 1–45 months), 3 patients were still alive 
at the end of the follow-up period. No significant differences 
in OS were seen between the cohorts  (see supplementary 
Fig. 5).
Discussion
Since mTOR based regimens lead to Treg expansion [16–18] 
which can be considered an undesirable effect in the treat-
ment of cancer, strategies that can selectively deplete Tregs 
might improve the antitumor effect of mTOR inhibitors by 
reversing the suppressive effect on the immune system. CTX 
was previously shown to result in selective Treg depletion 
[25, 26]; however, the optimal dose and schedule of metro-
nomic CTX to induce selective Treg depletion in patients 
treated with mTOR inhibitors has not been determined. In 
the present trial, the Treg depleting effect of several dos-
ages and schedules of metronomic CTX in combination with 
mTOR inhibition were investigated [27]. Our data indicate 
that a significant and selective Treg depletion in peripheral 
blood can be achieved when mRCC patients that receive 
the standard once daily oral dose of 10 mg everolimus are 
simultaneously treated with a once daily oral dose of 50 mg 
CTX, in a continuous scheme, whereas  CD4+ T cell per-
centages remain stable. The selected dose of CTX not only 
resulted in a significant decrease in the frequency of Tregs 
but also resulted in a significant decrease in absolute Treg 
numbers. Surprisingly, Treg percentages were found to actu-
ally increase when higher doses of CTX were administered. 
Since the exact mechanism responsible for Treg depletion is 
unknown, similarly this resistance of Tregs to higher CTX 
dosages remains unclear. Several mechanisms have been 
proposed to be responsible for the susceptibility of Tregs 
to CTX. For example, Tregs were shown (1) to have low 
ATP levels [31] leading to reduced synthesis of glutathione 
and thereby decreasing the detoxification of CTX, (2) to 
have DNA repair defects [32] due to high levels of DNA 
crosslinks and (3) to have deficient expression of ABCB1 
[33] making them less able to extrude CTX. On the other 
hand, it was shown that Tregs express aldehyde dehydroge-
nase (ALDH), protecting them from CTX toxicity in graft-
versus-host disease [34]. However, all those mechanisms 
cannot completely explain the observed effects, although it 
might be possible that Tregs acquire increased expression 
of ALDH, an effect that might be accelerated when higher 
dosages of cyclophosphamide are administered, possibly 
accounting for their apparent resistance to the depleting 
effects of CTX at these dose levels. Whether and which of 
these mechanisms may underlie the observed changes in the 
Treg population in the patients enrolled in this trial requires 
further investigation.
Across all the patient cohorts that were studied, we found 
that the combination of everolimus and CTX resulted in tox-
icity comparable to that observed in the RECORD-1 trial in 
patients with mRCC [35]. The toxicities that were observed 
in our trial were all known toxicities associated with both 
treatment regimens. The two observed DLTs, grade 3 pneu-
monitis in cohort 1 and grade 3 pancytopenia in combina-
tion with hyperglycemia in cohort 5, occurred in different 
cohorts, and therefore, did not affect further dose escalation 
of CTX. Common side effects of everolimus include lym-
phopenia, atypical infections, non-infectious pneumonitis 
and elevation of serum cholesterol, glucose, and triglycerides 
Fig. 3  Clinical outcome. a Best clinical response for the total study 
population. b Best clinical response shown per cohort. Partial remis-
sion (PR) is shown in black, stable disease (SD) in grey and progres-
sive disease (PD) in light grey
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[36]. Although these adverse events were observed in this 
trial, the most common side effects were fatigue, anorexia, 
rash, cough, mucositis, nausea, anemia, and hypercholes-
terolemia. Though everolimus is a known causative drug 
for these side effects, we cannot exclude an additional effect 
of CTX. All adverse events could be alleviated by adjust-
ment of the dose of the study drug or halting the study drug, 
and no deaths occurred due to the study medication. All 
cohorts were comparable with respect to the mean num-
ber of adverse events per patient, with a mean of 8.2 per 
patient. When patients were treated for a longer period with 
the study drugs, more adverse events were reported. The two 
cohorts with the highest CTX dose showed slightly more 
adverse events compared to the lower cohorts. Interestingly, 
addition of CTX to everolimus resulted in lower VEGF lev-
els compared to the cohort in which single everolimus treat-
ment was administered. These results were not statistically 
significantly different, probably due to small sample sizes 
and missing values at timepoint 8 weeks.
As secondary endpoints, the ORR, and median PFS and 
OS were calculated. Since the cohorts were small, only 5 
patients per cohort, the survival data were calculated for 
all patients combined as shown in Fig. 4 and supplemen-
tary Fig. 5, and additionally shown for all cohorts sepa-
rately. While the phase 2 part of the trial will allow formal 
assessment of the effect of the addition of the selected once 
daily oral dose of 50 mg of CTX on the clinical efficacy of 
everolimus, the data presented here at least show no sign 
of inferiority compared to historical results of everolimus 
monotherapy in mRCC.
In conclusion, in this trial we demonstrate that admin-
istration of 50 mg CTX once daily in a continuous sched-
ule leads to depletion of Tregs when combined with 10 mg 
everolimus once daily, with toxicity comparable to that 
reported in the RECORD-1 trial. The treatment combina-
tion is currently under investigation in a phase 2 trial, to 
determine if the observed Treg depletion also results in an 
enhancement of the survival of patients with mRCC when 
compared to everolimus alone. Recently everolimus was 
replaced by both nivolumab and cabozantinib as the stan-
dard second line treatment for patients with mRCC [7]. In 
case the phase 2 part of the trial shows beneficial effects on 
survival, combination therapy of CTX and everolimus could 
still be implemented in a later treatment line. However, when 
everolimus is combined with lenvatinib the additional effect 
of CTX might be limited as, e.g. the tyrosine kinase inhibi-
tor sunitinib, that like lenvatinib inhibits VEGF and other 
receptors [37, 38], was previously shown to decrease Treg 
frequencies [39, 40]. Besides, a sequential treatment sched-
ule of everolimus and cyclophosphamide could be proposed, 
which might result in reduced Treg levels with less toxicity. 
Since CTX is a well-known and broadly used drug, there is 
Fig. 4  Kaplan–Meier curves for PFS per cohort, compared to the total patient group
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much experience in the application of this drug. In addition, 
it is cheap, which is an advantage especially when compared 
to the cost of recently developed novel therapeutics. Fur-
thermore, since everolimus is registered for the treatment of 
pancreatic neuroendocrine tumors, these patients might also 
benefit from the same treatment combination [41].
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